REPETTO, MATTEO
REPETTO, MATTEO
Universita' degli Studi di MILANO
Molecular tumor board in patients with metastatic breast cancer
2025 L. Boscolo Bielo, E. Guerini Rocco, E. Crimini, M. Repetto, M. Lombardi, C. Zanzottera, G. Aurilio, M. Barberis, C. Belli, Y. Zhan, E. Battaiotto, J. Katrini, R. Marsicano, P. Zagami, B. Taurelli Salimbeni, A. Esposito, D. Trapani, C. Criscitiello, N. Fusco, A. Marra, G. Curigliano
Genomic landscape of breast cancer in elderly patients
2025 P. Selenica, H. Dopeso, M. Repetto, T. Basili, A.M. Gazzo, C.J. Schwartz, F. Derakhshan, A. Marra, L. Ferrando, R.G.H. Beets-Tan, Y.H. Wen, D.S. Ross, E. Brogi, H. Zhang, L. Norton, S. Chandarlapaty, P. Razavi, D. Mandelker, J.S. Reis-Fiho, B. Weigelt, F. Pareja
Molecular tumour board in gastrointestinal cancers
2025 L. Boscolo Bielo, E. Crimini, M. Repetto, M. Barberis, E. Battaiotto, J. Katrini, E. Martino, G. Gaudio, M. Lombardi, C. Zanzottera, G. Aurilio, C. Belli, Y. Zhan, V. Fuorivia, R.M. Marsicano, J.D. Etessami, P. Zagami, A. Marra, D. Trapani, B. Taurelli Salimbeni, C. Criscitiello, D. Ciardiello, B. Lavinia, L. Gervaso, C.A. Cella, F. Spada, M.G. Zampino, N. Fusco, N. Fazio, E. Guerini Rocco, G. Curigliano
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis
2024 L. Boscolo Bielo, M. Repetto, E. Crimini, C. Belli, E. Setola, G. Parma, N. Fusco, M. Barberis, E. Guerini Rocco, A. Marra, N. Colombo, G. Curigliano
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience
2024 E. Crimini, G. Tini, P. Tarantino, L. Ascione, M. Repetto, P. Beria, A. Ranghiero, A. Marra, C. Belli, C. Criscitiello, A. Esposito, E. Guerini Rocco, M.C.P. Barberis, L. Mazzarella, G. Curigliano
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
2024 L. Mazzarella, F. Giugliano, E. Nicolo, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. D'Amico, P.T. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P.P.M. Berton Giachetti, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit
2024 A. Esposito, E. Crimini, C. Criscitiello, C. Belli, R. Scafetta, R. Scalia, G. Castellano, E. Giordano, J. Katrini, L. Ascione, L. Boscolo Bielo, M. Repetto, A. Marra, D. Trapani, G.M. Varano, D. Maiettini, P. Della Vigna, F. Orsi, E. Guerini Rocco, N. Fusco, G. Curigliano
AI/ML and drug repurposing in lung cancer: State of the art and potential roles for retinoids
2024 G. Sala, D. La Torre, M. Repetto, G. Curigliano
Artificial intelligence in small-molecule drug discovery
2024 C. Martinelli, M. Repetto, G. Curigliano
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers
2024 C. Belli, L. Boscolo Bielo, M. Repetto, E. Crimini, R. Scalia, A. Diana, J. Orefice, L. Ascione, G. Pellizzari, N. Fusco, M. Barberis, B. Daniele, E. Guerini-Rocco, G. Curigliano
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology
2024 L. Boscolo Bielo, C. Belli, E. Crimini, M. Repetto, L. Ascione, G. Pellizzari, C. Santoro, V. Fuorivia, M. Barberis, N. Fusco, E.G. Rocco, G. Curigliano
High-performance prediction models for prostate cancer radiomics
2023 L.J. Isaksson, M. Repetto, P.E. Summers, M. Pepa, M. Zaffaroni, M.G. Vincini, G. Corrao, G.C. Mazzola, M. Rotondi, F. Bellerba, S. Raimondi, Z. Haron, S. Alessi, P. Pricolo, F.A. Mistretta, S. Luzzago, F. Cattani, G. Musi, O. De Cobelli, M. Cremonesi, R. Orecchia, D. La Torre, G. Marvaso, G. Petralia, B.A. Jereczek-Fossa
A dynamic approach to supply chain reconfiguration and ripple effect analysis in an epidemic
2023 X. Brusset, D. Ivanov, A. Jebali, D. La Torre, M. Repetto
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience
2023 M. Repetto, E. Crimini, L. Boscolo Bielo, E. Guerini-Rocco, L. Ascione, A. Bonfanti, C. Zanzottera, L. Mazzarella, A. Ranghiero, C. Belli, C. Criscitiello, A. Esposito, M.C.P. Barberis, G. Curigliano
The emerging role of PI3K inhibitors for solid tumour treatment and beyond
2023 C. Belli, M. Repetto, S. Anand, C. Porta, V. Subbiah, G. Curigliano
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data
2023 M. Repetto, E. Crimini, C. Belli, L. Boscolo Bielo, L. Ascione, F. Meric-Bernstam, A. Drilon, G. Curigliano
Antibody-Drug Conjugates in Breast Cancer: What Is beyond HER2?
2022 E. Nicolo, M. Repetto, L. Boscolo Bielo, P. Tarantino, G. Curigliano
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population
2022 L. Mazzarella, E. Nicolò, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. Trillo Aliaga, C. Valenza, M. Repetto, G. Antonarelli, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046
2022 M. Repetto, E. Crimini, L. Ascione, L. Boscolo Bielo, C. Belli, G. Curigliano
Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards
2022 E. Crimini, M. Repetto, P. Tarantino, L. Ascione, G. Antonarelli, E.G. Rocco, M. Barberis, L. Mazzarella, G. Curigliano